TacticScaleWhat Omnicell Does & How It Makes Money (OMCL)
Updated October 2026 · reflects Omnicell's latest reported financials
Pharmacy automation and medication-management technology for hospitals and pharmacies. It sells automation hardware and consumables, and earns recurring revenue from software, cloud and specialty pharmacy services, plus installation, training and ongoing maintenance and support contracts.
How Omnicell makes money
It sells automation hardware and consumables, and earns recurring revenue from software, cloud and specialty pharmacy services, plus installation, training and ongoing maintenance and support contracts.
What Omnicell does
Omnicell, Inc. is a Fort Worth, Texas-based healthcare technology company that automates how medications are handled, from the central pharmacy to the patient bedside. For hospitals and health systems, it offers point-of-care dispensing cabinets such as Titan XT (with XTExtend console upgrades for existing XT cabinets), plus central pharmacy dispensing and automation services and in-house IV compounding. Its cloud-based OmniSphere platform connects these tools, and it also sells products for tracing medicines and medical supplies across the healthcare system. Beyond hospitals, Omnicell serves retail and community pharmacies through its EnlivenHealth digital platform and medication adherence packaging and consumables. It also offers turnkey specialty pharmacy services for health systems, along with implementation, training, program management and post-installation support. The company was incorporated in 1992, was formerly called Omnicell Technologies, and operates in the U.S. and internationally.
Products & services
- Titan XT automated dispensing system
- XTExtend
- Central Med Automation Service
- IV Compounding Service
- EnlivenHealth
- OmniSphere
What is Omnicell worth?
On an owner-earnings DCF, Omnicell's most-likely value is about $57 versus a recent price near $36 (58% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$28) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
ICU Medical (ICUI) · Insulet (PODD) · CVS Health (CVS) · McKesson (MCK) · Cardinal Health (CAH)